Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 76 Pretax Margin % is 12.19% as of Dec. 2025, which is 0% above its 10-year median of 12.13. GuruFocus rates ROCO:3118 with a GF Score™ of 76/100 and a GF Value™ of NT$35.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Level Biotechnology ranks better than 81.63% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Level Biotechnology Pretax Margin % Related Terms
Level Biotechnology Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Level Biotechnology's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology (ROCO:3118) has a Pretax Margin % of 12.19% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Level Biotechnology and its competitors. This is near median its historical median of 12.13. Over the past decade, Level Biotechnology's Pretax Margin % has ranged from 7.83 to 14.89. According to the industry distribution chart, Level Biotechnology ranks #173 out of 942 companies in the Biotechnology industry, placing it in the top 18.4%.
Is Level Biotechnology's Pretax Margin % too high?
Level Biotechnology's current Pretax Margin % of 12.19% is near median its 10-year median of 12.13. Over the past 10 years, this metric has ranged from a low of 7.83 to a high of 14.89. Based on the distribution chart, Level Biotechnology ranks #173 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Level Biotechnology has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #173 out of 942 companies for Pretax Margin %. This places Level Biotechnology in the top 18% of its industry — outperforming the majority of peers. Historically, Level Biotechnology's own Pretax Margin % has ranged from 7.83 to 14.89 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Level Biotechnology and its competitors. Level Biotechnology's current Pretax Margin % is 12.19%, which is near median its own 10-year median of 12.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$35.57, compared to a current price of NT$31.75 — trading 10.7% below its estimated fair value. The current Pretax Margin % is 12.19%, which is near median its 10-year median of 12.13. Level Biotechnology's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current Pretax Margin % is 12.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.75 is trading 10.7% below its estimated GF Value™ of NT$35.57.
GuruFocus considers Level Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3118:
Pretax Margin %: 12.19% (near median its 10-year median of 12.13)
GF Value™: NT$35.57 vs. price of NT$31.75 (10.7% below fair value)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
76GF Score
Get the complete analysis for ROCO:3118
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
